MicroRNA Could Help Diagnose Mental Disorders
By LabMedica International staff writers Posted on 02 Jul 2014 |
The link between dysregulated serotonergic activity and depression and anxiety disorders is well established, yet the molecular mechanisms underlying these psychopathologies are not fully understood.
The etiology of depression and/or anxiety disorders is a complex interaction between environmental factors and genetic predisposition, possibly suggesting a mechanistic role for epigenetic processes, and such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease.
Scientists at the Weizmann Institute of Science (Rehovot, Israel) investigated the molecular mechanisms of the brain's serotonin system, which, when misregulated, is involved in depression and anxiety disorders. They explored the role of micro ribonucleic acid (miRNA) molecules in the nerve cells that produce serotonin.
Total RNA was isolated using the PAXgene Blood RNA Kit (QIAGEN; Valencia, CA, USA) from both mice and human subjects. The team identified for the first time, the unique "fingerprints" of a microRNA molecule that acts on the serotonin-producing nerve cells. Combining bioinformatics methods with experiments, they found a connection between a particular microRNA, miR135, and two proteins that play a key role in serotonin production and the regulation of its activities. The scientists noted that in the area of the brain containing the serotonin-producing nerve cells, miR135 levels increased when antidepressant compounds were introduced.
The investigators found that subjects who suffered from depression had unusually low miR135 levels in their blood. On closer inspection, the scientists discovered that the three genes involved in producing miR135 are located in areas of the genome that are known to be associated with risk factors for bipolar mood disorders. The authors concluded that their findings suggest that miR135 could be a useful therapeutic molecule, both as a blood test for depression and related disorders, and as a target whose levels might be raised in patients. The study was published on June 19, 2014, in the journal Neuron.
Related Links:
Weizmann Institute of Science
QIAGEN
The etiology of depression and/or anxiety disorders is a complex interaction between environmental factors and genetic predisposition, possibly suggesting a mechanistic role for epigenetic processes, and such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease.
Scientists at the Weizmann Institute of Science (Rehovot, Israel) investigated the molecular mechanisms of the brain's serotonin system, which, when misregulated, is involved in depression and anxiety disorders. They explored the role of micro ribonucleic acid (miRNA) molecules in the nerve cells that produce serotonin.
Total RNA was isolated using the PAXgene Blood RNA Kit (QIAGEN; Valencia, CA, USA) from both mice and human subjects. The team identified for the first time, the unique "fingerprints" of a microRNA molecule that acts on the serotonin-producing nerve cells. Combining bioinformatics methods with experiments, they found a connection between a particular microRNA, miR135, and two proteins that play a key role in serotonin production and the regulation of its activities. The scientists noted that in the area of the brain containing the serotonin-producing nerve cells, miR135 levels increased when antidepressant compounds were introduced.
The investigators found that subjects who suffered from depression had unusually low miR135 levels in their blood. On closer inspection, the scientists discovered that the three genes involved in producing miR135 are located in areas of the genome that are known to be associated with risk factors for bipolar mood disorders. The authors concluded that their findings suggest that miR135 could be a useful therapeutic molecule, both as a blood test for depression and related disorders, and as a target whose levels might be raised in patients. The study was published on June 19, 2014, in the journal Neuron.
Related Links:
Weizmann Institute of Science
QIAGEN
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans